Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management.

Tran, NH; Sais, D; Tran, N

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management.

Tran, NH Sais, D

Tran, N

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: J Med Virol, 2024, 96, (6), pp. e29746
Issue Date:: 2024-06

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.55 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Tran, NH
dc.contributor.author	Sais, D https://orcid.org/0000-0002-5859-1398
dc.contributor.author	Tran, N https://orcid.org/0000-0001-7747-2530
dc.date.accessioned	2024-11-05T02:10:25Z
dc.date.available	2024-06-08
dc.date.available	2024-11-05T02:10:25Z
dc.date.issued	2024-06
dc.identifier.citation	J Med Virol, 2024, 96, (6), pp. e29746
dc.identifier.issn	0146-6615
dc.identifier.issn	1096-9071
dc.identifier.uri	http://hdl.handle.net/10453/181741
dc.description.abstract	Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high-risk human papillomavirus (HR HPV), notably HPV16 and HPV18. HPV status guides treatment and predicts outcomes, with distinct molecular pathways in HPV-driven HNSCC influencing survival rates. HNC incidence is rising globally, with regional variations reflecting diverse risk factors, including tobacco, alcohol, and HPV infection. Oropharyngeal cancers attributed to HPV have significantly increased, particularly in regions like the United States. The HPV16 genome, characterized by oncoproteins E6 and E7, disrupts crucial cell cycle regulators, including tumor protein p53 (TP53) and retinoblastoma (Rb), contributing to HNSCC pathogenesis. P16 immunohistochemistry (IHC) is a reliable surrogate marker for HPV16 positivity, while in situ hybridization and polymerase chain reaction (PCR) techniques, notably reverse transcription-quantitative PCR (RT-qPCR), offer sensitive HPV detection. Liquid-based RT-qPCR, especially in saliva, shows promise for noninvasive HPV detection, offering simplicity, cost-effectiveness, and patient compliance. These molecular advancements enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in HNC management. In conclusion, advances in HPV detection and molecular understanding have significant clinical management implications. Integrating these advancements into routine practice could ultimately improve patient outcomes.
dc.format	Print
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	J Med Virol
dc.relation.isbasedon	10.1002/jmv.29746
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0605 Microbiology, 1108 Medical Microbiology
dc.subject.classification	Virology
dc.subject.classification	3107 Microbiology
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3207 Medical microbiology
dc.subject.mesh	Humans
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Human papillomavirus 16
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Human papillomavirus 18
dc.subject.mesh	Human Papillomavirus Viruses
dc.subject.mesh	Humans
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Human papillomavirus 18
dc.subject.mesh	Human papillomavirus 16
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Human Papillomavirus Viruses
dc.subject.mesh	Humans
dc.subject.mesh	Papillomavirus Infections
dc.subject.mesh	Head and Neck Neoplasms
dc.subject.mesh	Squamous Cell Carcinoma of Head and Neck
dc.subject.mesh	Human papillomavirus 16
dc.subject.mesh	Papillomaviridae
dc.subject.mesh	Human papillomavirus 18
dc.subject.mesh	Human Papillomavirus Viruses
dc.title	Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management.
dc.type	Journal Article
utslib.citation.volume	96
utslib.location.activity	United States
utslib.for	0605 Microbiology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2024-11-05T02:10:22Z
pubs.issue	6
pubs.publication-status	Published
pubs.volume	96
utslib.citation.issue	6

Abstract:

Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high-risk human papillomavirus (HR HPV), notably HPV16 and HPV18. HPV status guides treatment and predicts outcomes, with distinct molecular pathways in HPV-driven HNSCC influencing survival rates. HNC incidence is rising globally, with regional variations reflecting diverse risk factors, including tobacco, alcohol, and HPV infection. Oropharyngeal cancers attributed to HPV have significantly increased, particularly in regions like the United States. The HPV16 genome, characterized by oncoproteins E6 and E7, disrupts crucial cell cycle regulators, including tumor protein p53 (TP53) and retinoblastoma (Rb), contributing to HNSCC pathogenesis. P16 immunohistochemistry (IHC) is a reliable surrogate marker for HPV16 positivity, while in situ hybridization and polymerase chain reaction (PCR) techniques, notably reverse transcription-quantitative PCR (RT-qPCR), offer sensitive HPV detection. Liquid-based RT-qPCR, especially in saliva, shows promise for noninvasive HPV detection, offering simplicity, cost-effectiveness, and patient compliance. These molecular advancements enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in HNC management. In conclusion, advances in HPV detection and molecular understanding have significant clinical management implications. Integrating these advancements into routine practice could ultimately improve patient outcomes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181741